Appeal Court supported FAS refusal to agree upon the fivefold increase of price for “Sulpride”
FAS insists that generics should not cost more that reference drugs
On 12 December 2016, the 9th Arbitration Appeal Court pronounced legitimacy of the position of the Federal Antimonopoly Service (FAS Russia) that had refused “SVICH” Ltd. to agree the maximum ex-works prices for “Sulpride”neuroleptic agent (oral solution).
The company failed to apply the reducing coefficient from the price for the reference (original) drug, although this norm came into effect 1 October 2015.
“Carrying out economic analysis, FAS established that the cost of “Sulpride”generic drug was 4.7 times higher in comparison with “Eglonil” reference drug in the form of tablets”, said Deputy Head of FAS Department for Control over Social Sphere and Trade, Nadezhda Sharavskaya.
The decision of the antimonopoly authority formed the grounds for the Ministry of Health Care to refuse official registration of the maximum ex-work price for “Sulpride”.